Auto logout in seconds.
Continue Logout
Pfizer will acquire Metsera, an obesity drug developer, for roughly $10 billion, ending a bidding war with Novo Nordisk over the company, in today's bite-sized hospital and health industry news from Missouri, New York, and Utah.
- Missouri: Several technology and consulting companies have partnered to form the Collaborative for Healthy Rural America, which aims to use AI-backed technology to expand care access and lower costs for rural hospitals and providers. Companies involved with the collaborative include Lumeris, Teladoc Health, Nuna, Deloitte, and Unite Us. The coalition plans to target initiatives under the Rural Health Transformation Fund, a $50 billion fund created by the One Big Beautiful Bill Act. The fund will disburse $10 billion per year for five years to states that successfully pitch the program to increase provider pay, recruit staff, and more in rural areas. According to John Fryer, chief growth and corporate development officer at Lumeris, the Collaborative for Healthy Rural America can help states get their programs up and running quickly. "To solve some of these problems facing rural communities at scale, which is what the federal government is looking to do, this collaboration can drive economies of scale and infrastructure development across state boundaries that can lead to higher quality care, improve access and bend the cost curve," Fryer said. In the future, Lumeris, which is spearheading the project, said it hopes other companies will join the coalition to offer their technology and resources to healthcare stakeholders. (Kacik, Modern Healthcare, 11/3)
- New York: Pfizer has agreed to acquire obesity care startup Metsera for $10 billion, ending a bidding war with Novo Nordisk over the company. Previously, Pfizer agreed to acquire Metsera for up to $7.3 billion. However, Novo Nordisk made its own separate, unsolicited offer for Metsera, including an equity value of roughly $6.5 billion and another $2.5 billion in case certain clinical and regulatory milestones were met. Novo's offer set off a bidding war for the company, with Pfizer suing both Novo and Metsera over an alleged breach of contract and anticompetitive practices. On Friday, Metsera announced it had agreed to be acquired by Pfizer for up $86.25 per share, or around $10 billion. "We are pleased that we and Metsera have agreed to these revised terms, which will provide immediate and certain value to Metsera's shareholders," Pfizer said in a statement. According to both companies, the deal will be finalized after Metsera's shareholder meeting on Nov. 13. (Primack, Axios, 11/7; Regalado, New York Times, 11/8)
- Utah: Chris Gibson, CEO and co-founder of the techbio company Recursion, is stepping down from the role after 12 years. Najat Khan, the company's head of research and development and chief commercial officer, will succeed Gibson as CEO, effective Jan. 1. Khan joined Recursion in 2024. Previously, Khan served as the chief data science officer in Johnson & Johnson's medicines division. "I'm excited to lead our next phase — turning platform insights into clinical proof, scaling where we have a true edge, and ultimately delivering transformational medicines for patients," Khan said. Although Gibson is stepping down as CEO, he is not completely leaving the company. Instead, he will become chair of the company's board. "I feel really proud of everything that we've done, and I don't regret pushing really hard to try and shake things up a little bit," Gibson said. (Trang, STAT+ [subscription required], 11/5)
Don't miss out on the latest Advisory Board insights
Create your free account to access 1 resource, including the latest research and webinars.
Want access without creating an account?
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Become a member to access all of Advisory Board's resources, events, and experts
Never miss out on the latest innovative health care content tailored to you.
Benefits include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
You've reached your limit of free insights
Become a member to access all of Advisory Board's resources, events, and experts
Never miss out on the latest innovative health care content tailored to you.
Benefits include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board
Never miss out on the latest innovative health care content tailored to you.
Benefits Include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
This is for members only. Learn more.
Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board
Never miss out on the latest innovative health care content tailored to you.
Benefits Include:
Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
